Platelet Rich Plasma for Knee Arthritis

(PRP-PEPC Trial)

Overseen By Jocelyn Carpio

Age: 18+

Sex: Any

Trial Phase: Phase 4

Sponsor: University of California, San Francisco

Must not be taking: Chemotherapy, Prednisone, Anti-inflammatories

Disqualifiers: Severe arthritis, Rheumatologic disease, Cancer, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: 1

Duration: 1 day

What You Need to Know Before You Apply

What is the purpose of this trial?

The investigators would like to study the differences in the quality of Platelet Rich Plasma (PRP) between two different machines in those with knee osteoarthritis. Knee osteoarthritis means your cartilage has been worn down, and it affects your knee joint. Both machines, the APEX Biologix XCELL PRP System and the Emcyte PurePRP Supraphysiologic Concentrating System, are FDA approved, commercially available, and makes PRP. The investigators will check if the platelets in the PRP have different amounts or work differently. The investigators will also assess participants symptoms after the injection and compare the two different preparation systems.

Who Is on the Research Team?

Anthony Luke, MD

Principal Investigator

University of California, San Francisco

Are You a Good Fit for This Trial?

Inclusion Criteria

Will be able to attend and perform physical therapy

My knee osteoarthritis is mild to moderate.

I have had knee osteoarthritis symptoms in one knee for at least 3 months.

Exclusion Criteria

I have had injection therapy for my knee osteoarthritis in the last 6 months.

Both my knees have osteoarthritis, and my other knee has moderate or worse damage.

Have uncontrolled illness, physical disability, or other contraindication to aerobic exercise training

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive Platelet Rich Plasma injections using either the APEX Biologix XCELL PRP System or the Emcyte PurePRP Supraphysiologic Concentrating System

1 day

1 visit (in-person)

Follow-up

Participants are monitored for changes in symptoms and PRP characteristics over time

6 months

Multiple assessments (in-person and virtual)

What Are the Treatments Tested in This Trial?

Interventions

• Platelet Rich Plasma

How Is the Trial Designed?

Group I: APEX Biologix XCELL PRP System Active Control 2 Interventions

Participants in this group will receive Platelet Rich Plasma made by the APEX Biologix XCELL PRP System.

Group II: Emcyte PurePRP Supraphysiologic Concentrating System Active Control 2 Interventions

Participants in this group will receive Platelet Rich Plasma made by Emcyte PurePRP Supraphysiologic Concentrating System.

Who Is Running the Clinical Trial?

University of California, San Francisco

Lead Sponsor

Trials

2,636

Recruited

19,080,000+